Friday, February 10, 2012 3:44:35 PM
I revisited the Amylin-inVentiv Deal and thought that it might imply something:
Why AMLN does not create a sale force for Bydureon if the company want to make big $$$ on this blockbuster drug?
Why AMLN said in the agreement that it can notify inVentiv 60 days in advance to terminate the deal if necessary?
The deal at the time when the drug received FDA approval tell me that AMLN wants to sell the company to a big pharma that may have a well established diabetes sale force; thus AMLN does not have to layoff new hires for Bydureon commercial.
I think that AMLN will be taken over in the next 12 to 24 months.
What do you think?
All the best!
WID
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM